HIV infection remains a worldwide concern and new drug treatments are required to tackle drug resistance and to reduce drug-associated host toxicity. Raltegravir, a new anti-HIV drug which targets the HIV integrase enzyme, is now being used in anti-HIV treatment and has shown impressive efficacy and low toxicity. However, the drug shows high pharmacokinetic (PK) variability between subjects and it has been difficult to associate PK parameters with treatment outcome. The aim of this thesis was to improve the current understanding of the factors influencing raltegravir PK and cellular exposure using in vitro and in silico techniques.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:632138 |
| Date | January 2012 |
| Creators | Moss, Darren |
| Publisher | University of Liverpool |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.0021 seconds